You are viewing: US Long Read Sequencing Market analysis
Part of: Long Read Sequencing Market (Global)

The US Long Read Sequencing Market was valued at $175.9 Million in 2024 and projected to reach to $740.4 Million by 2029, representing a compound annual growth rate of 33.3%. The US long read sequencing market is poised for transformative growth through 2029, driven by declining sequencing costs, expanding clinical applications, and increasing healthcare provider adoption.

US Long Read Sequencing Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Long Read Sequencing Market Trends and Insights

  • This robust growth reflects the US healthcare sector's increasing adoption of advanced genomic technologies for clinical diagnostics, research applications, and precision medicine initiatives.
  • The US market benefits from substantial investments in biotechnology infrastructure, strong regulatory frameworks, and a concentration of leading sequencing technology providers and research institutions. Driving this expansion, the US is witnessing heightened demand for long read sequencing across oncology, rare disease diagnosis, and infectious disease monitoring.
  • US pharmaceutical and diagnostic companies are integrating long read platforms into their workflows to improve accuracy and reduce turnaround times.
  • The competitive landscape in the US remains dynamic, with both established players and emerging innovators competing to capture market share through technological advancement and strategic partnerships..

Key Market Statistics

  • CAGR (2024-2029) 33.3% CAGR
  • Market Size, 2024 ~USD 175.9 Million
  • Forecast, 2029 ~USD 740.4 Million
  • Country US

US Long Read Sequencing Market Overview

Rapid US Market Expansion :

The US long read sequencing market is experiencing exceptional growth, expanding from $175.9 million in 2024 to $740.4 million by 2029, representing a 33.3% CAGR. This growth trajectory significantly outpaces global averages, positioning the US as a leading market for advanced genomic technologies.

Clinical Diagnostics Adoption :

US healthcare providers are increasingly integrating long read sequencing into clinical diagnostic workflows for rare disease identification, cancer genomics, and structural variant detection. This shift is driven by improved reimbursement policies and growing clinical evidence supporting diagnostic accuracy.

Precision Medicine Investment :

US biotech and pharmaceutical companies are heavily investing in long read sequencing for precision medicine applications, drug development, and personalized treatment strategies. Federal funding initiatives and private sector investments are accelerating technology adoption across research institutions and clinical laboratories.

Technology Infrastructure Growth :

The US market benefits from established sequencing infrastructure, skilled workforce, and competitive vendor landscape. Major academic medical centers and commercial laboratories are expanding long read capabilities, creating ecosystem-wide momentum for market penetration and innovation.

US Long Read Sequencing Market Dynamics

  • Regulatory approvals for long read-based diagnostics and growing insurance coverage are removing adoption barriers, particularly in oncology and rare disease diagnosis.
  • The US market will benefit from substantial NIH and NSF funding for genomic research initiatives and precision medicine programs. Key growth catalysts include integration of long read sequencing into mainstream clinical laboratories, development of standardized protocols, and emergence of AI-powered data analysis platforms.
  • US healthcare systems' focus on improving diagnostic accuracy and reducing time-to-diagnosis will drive sustained demand.
  • Strategic partnerships between sequencing technology providers and clinical laboratory networks will accelerate market expansion, positioning the US as the global leader in long read sequencing adoption and innovation..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The US long read sequencing market will grow from $175.9M (2024) to $740.4M (2029), representing a 33.3% CAGR.
    • US clinical laboratories and research institutions are rapidly adopting long read technologies for improved diagnostic accuracy and genomic insights.
    • The US market is driven by increasing prevalence of genetic disorders, cancer genomics applications, and precision medicine initiatives across healthcare systems.
    • US regulatory support and reimbursement pathways are accelerating commercialization and clinical integration of long read sequencing platforms.

    Long Read Sequencing Market Report Scope

    Report Metric Details
    Base Year 2024
    Fastest Growing Segment DATA ANALYSIS (Workflow)
    Forecast Period 2024-2029
    Growth Rate CAGR of 32.8% from 2024 to 2029
    Largest Segment RESEARCH USAGE (Usage)
    Market Size Base Year (Billions) ~USD 0.76 (2024)
    Revenue Forecast (Billions) ~USD 3.13 (2029)
    Segments Covered Offering, Technology, Workflow, Application, Usage, End User

    US Long Read Sequencing Market Report Segmentation

    6 segment dimensions are covered across the global market.

    By Offering

    • Consumables
    • Instruments
    • Services

    By Technology

    • Nanopore Sequencing
    • Single-Molecule Real-Time Sequencing
    • Synthetic Long-Read Sequencing

    By Workflow

    • Data Analysis
    • Sample Preparation
    • Sequencing

    By Application

    • Epigenetics
    • Metagenomics
    • Other Applications
    • Targeted Sequencing
    • Whole-Exome Sequencing
    • Whole-Genome Sequencing

    By Usage

    • Clinical Usage
    • Research Usage

    By End User

    • Academic & Research Institute
    • Academic & Research Institutes
    • Hospitals, Clinics & Diagnostic
    • Hospitals, Clinics, And Diagnostic Labs
    • Other End User
    • Other End Users
    • Pharmaceutical & Biotechnologies Companies
    • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical & Biotechnology Companies Labs

    US: LONG-READ SEQUENCING MARKET, BY END USER, 2022–2029

    Segment20222023202420252026202720282029CAGR (%)
    ACADEMIC & RESEARCH INSTITUTE85114.1145.4188.2247.1328.1439.2610.633.2
    HOSPITALS, CLINICS, AND DIAGNOSTIC LABS28.738.849.86586114.915521734.2
    OTHER END USERS16.22125.832.140.551.766.388.227.9
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES37.750.46482.6108.2143.2191.126532.8
    TOTAL167.5224.2285.1367.9481.9637.9851.61180.832.9

    Target Audience

    • Biotech & Sequencing Companies : US-based and international sequencing technology providers need market intelligence to guide product development, clinical validation strategies, and go-to-market approaches tailored to the American healthcare system and competitive dynamics.
    • Clinical Laboratory Networks : Diagnostic laboratories and hospital systems require data on market trends, clinical applications, and adoption benchmarks to justify investments in long read sequencing infrastructure and develop service offerings for US healthcare providers.
    • Pharmaceutical & Biotech R&D : US pharmaceutical companies and research institutions need insights into long read sequencing adoption for drug development, genomic research, and precision medicine programs to optimize R&D investments and accelerate innovation timelines.
    • Healthcare Investors & Consultants : Venture capital firms, private equity investors, and management consultants require comprehensive US market data to evaluate investment opportunities, assess company valuations, and develop strategic recommendations for healthcare technology clients.
    • Healthcare Policy & Payers : Insurance companies, CMS, and healthcare policy organizations need market analysis to inform reimbursement policies, coverage decisions, and healthcare economics assessments for long read sequencing in the US healthcare system.

    Reasons to Buy this Report

    • US-Specific Market Sizing : Obtain precise market valuation and forecasting data exclusive to the US market, enabling accurate budgeting, investment decisions, and competitive positioning within the American healthcare and biotech sectors.
    • Clinical Adoption Insights : Understand US-specific clinical adoption patterns, reimbursement landscape, and regulatory pathways for long read sequencing. Identify opportunities in hospital systems, diagnostic laboratories, and precision medicine centers across different US regions.
    • Competitive Landscape Analysis : Gain detailed intelligence on US-based and international competitors operating in the American market, including market share, technology differentiation, and strategic positioning to inform competitive strategy and partnership opportunities.
    • Investment & Growth Opportunities : Identify high-growth segments within the US market, emerging applications in oncology and rare diseases, and funding trends. Leverage data to support venture capital decisions, M&A strategies, and market entry planning for US expansion.
    • Regulatory & Reimbursement Guidance : Access US-specific regulatory requirements, FDA approval pathways, and insurance reimbursement trends for long read sequencing. Understand coverage policies and payer perspectives to optimize commercialization strategies and market access planning.

    Frequently asked questions

    What is the current size of the US long read sequencing market?

    The US long read sequencing market was valued at $175.9 million in 2024 and is expected to grow to $740.4 million by 2029.

    What is the projected growth rate for the US long read sequencing market?

    The US long read sequencing market is projected to grow at a compound annual growth rate (CAGR) of 33.3% from 2024 to 2029.

    Which applications are driving growth in the US long read sequencing market?

    Key applications driving US market growth include oncology diagnostics, rare disease identification, infectious disease monitoring, and structural variant detection in precision medicine.

    What factors are accelerating long read sequencing adoption in the US?

    US adoption is accelerated by improved reimbursement policies, FDA approvals for clinical applications, growing demand for personalized medicine, and declining sequencing costs.

    Who are the major players in the US long read sequencing market?

    The US market includes established technology providers, diagnostic companies, and emerging startups competing through innovation in sequencing platforms, accuracy improvements, and clinical applications.

    RESEARCH METHODOLOGY

    This study on the long-read sequencing market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the long-read sequencing market using several research strategies, the size of the final market was obtained by triangulating data from primary research.

    Secondary Research

    The secondary sources referred to for this research study include publications from government sources. These include Nucleic Acids Research, Genome Biology, Nature Reviews Genetics, Nature Methods, Genome Research, International Journal of Genomics, National Human Genome Research Institute (NHGRI), International Chromosome and Genome Society (ICGS), Genome Canada, European Society of Human Genetics (ESHG), Genomics England, Genome British Columbia, Beijing Institute of Genomics, Centre for Cellular & Molecular Biology (CCMB), São Paulo Research Foundation (FAPESP), National Cancer Institute (NCI), European Medicines Agency (EMA), Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Population Health Research Institute (PHRI),  PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global long-read sequencing market, which was validated through primary research.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global long-read sequencing market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing long-read sequencing; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Long Read Sequencing Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the long-read sequencing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Bottom-up Approach

    • The key players in the industry and market have been identified through extensive secondary research.
    • The revenues generated from the long-read sequencing market business of leading players have been determined through primary and secondary research.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Long Read Sequencing Market Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Top-down Approach

    After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

    Long Read Sequencing Market Size, and Share

    Data Triangulation

    To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Long-read sequencing is a type of nucleic acid sequencing that produces genomic data by generating individual reads from single molecules, generally ranging in size from 700 to over 20,000 bases. These fragments are typically derived from "native" molecules, which are directly extracted from biological samples for analysis. The long-read sequencing market encompasses the consumables, instruments, services, and technology associated with long-read sequencing. The long-read sequencing market is defined as solutions including instruments/systems, consumables (kits, reagents, flow cells), and services for long-read sample preparation, sequencing, and data analysis. Long-read software solutions are often provided alongside the instrument/system/platform, hence the software solutions are considered within the instrument segment scope. Other standalone software solutions are provided as data analysis services and are considered within the services segment scope.

    Stakeholders

    • Academic & Research Institutes
    • Software & Bioinformatics Companies
    • Healthcare & Clinical Laboratories
    • Long-Read Sequencing Technology Vendors
    • Contract Research Organizations (CROs)
    • Market Research and Consulting Firms
    • Pharmaceutical & Biotechnology Companies
    • Regulatory Agencies
    • Venture Capitalists
    • Government Organizations
    • Industry Associations and Professional Societies

    Report Objectives

    • To define, describe, and forecast the long-read sequencing market based on offerings, technology, workflow, application, usage, end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall long-read sequencing market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the global long-read sequencing market and comprehensively analyze their instruments, consumables, and services portfolios, market positions, and core competencies
    • To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the long-read sequencing market
    • To benchmark players within the long-read sequencing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe Long-Read Sequencing Market, by country
    • Further breakdown of the Rest of Asia Pacific Long-Read Sequencing Market, by country
    • Further breakdown of the Rest of Latin America Long-Read Sequencing Market, by country
    • Further breakdown of the Rest of Middle East Long-Read Sequencing Market, by country

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Further breakdown of the other application and other end users area into subsegments
    • Cross-segment analysis

    Get the Full Long Read Sequencing Market Report

    Full forecast, segment splits, and company analysis for all Long Read Sequencing Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status